Alaunos Therapeutics
TCRT
77 hedge funds and large institutions have $159M invested in Alaunos Therapeutics in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
91% more capital invested
Capital invested by funds: $83.2M → $159M (+$75.7M)
10% more funds holding
Funds holding: 70 → 77 (+7)
9% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $3.88M
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$2.35M |
| 2 |
Barclays
London,
United Kingdom
|
+$1.16M |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$753K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$710K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$657K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$1.86M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$389K |
| 3 |
RA
Royce & Associates
New York
|
-$252K |
| 4 |
Jane Street
New York
|
-$241K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$231K |
TCRT Hedge Fund Activity: Q3 2013 in Review
77 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2013, worth a combined $159M — up 91% from $83.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TCRT positions and 6 closed out — a net gain of 8 holders — while 22 added to existing stakes and 21 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $2.35M. The largest seller was SAC Capital Advisors, exiting entirely with an estimated $1.86M sold.
- 77 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2013, up from 70 in Q2 2013.
- Funds reported $159M of Alaunos Therapeutics stock for Q3 2013, up 91% quarter-over-quarter.
- 14 funds opened new Alaunos Therapeutics positions in Q3 2013 and 6 closed out, a net change of +8 holders.
- The largest Alaunos Therapeutics buyer in Q3 2013 was Jennison Associates, an estimated $2.35M added.
- The largest Alaunos Therapeutics seller in Q3 2013 was SAC Capital Advisors, an estimated $1.86M sold.
Based on aggregated 13F filings for Q3 2013.